11 December 2015 - The draft recommendations say that olaparib should be available for people only if they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months is met by AstraZeneca.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-intends-to-recommend-olaparib-for-ovarian-fallopian-tube-and-peritoneal-cancer-after-company-provides-more-information